Telix signs PI Medical as distribution partner in Netherlands
Author : Pankaj Singh | Published Date : 2019-07-03
PI Medical to receive exclusive rights to distribution of TLX591- CDx in Netherlands
Australia headquartered - Telix Pharmaceuticals, a clinical stage biopharma company has reportedly signed Netherlands- based PI Medical Diagnostic Equipment for the distribution of TLX591-CDx cold kit in Netherlands.
For the record, Telix Pharmaceuticals focuses on the development of therapeutic and diagnostic development of products based on molecularly targeted radiation (MTR). Based in Melbourne, the company has international presence in Japan, Europe and United States. Currently, the company is developing a portfolio of clinical stage cancer treatment products that meet the required need for brain, renal and prostate cancer treatment.
Ludovic Wouters, VP Corporate Development at Telix Pharmaceuticals was reportedly quoted stating that for several months the company has been informally researching and working with the PI Medical and aim at establishing a concrete commercial relationship focusing on the availability of PSMA imaging cold kit. With the help of PI Medical’s nuclear medicine expertise and their recognition in the market, Telix Pharmaceuticals can easily establish itself in the Dutch market, he further stated.
PI Medical Diagnostic Equipment was founded in January 1995 and is a commercially strong Netherlands based company produces nuclear medicines and focuses on radiology and radiotherapy market. The company has developed equipments for sentinel gland procedures. The products range from nuclear medicines, radiotherapy, radiology to operating rooms.
The Managing Director of PI Medical reportedly claimed that the collaborating companies complement each other, concerning PI’s expertise in nuclear medicines and Telix’s products. The theranostic product portfolio of the company includes gallium-based products and the use of Lutetium- 177, a therapeutic isotope, he added.
The collaboration is a multi-product agreement whereby PI Medical will receive the exclusive rights to the distribution of TLX591 – CDx, a prostate cancer imaging in Netherlands and non- exclusive distribution rights in the Flemish region of Belgium.
Reportedly, the financial details related to the deal have not been disclosed so far.
About Author
Pankaj Singh . .
Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605
Related News
Bayers new CEO initiates management job cuts to accelerate decision-making
Bayer newly appointed CEO, Bill Anderson, has reportedly unveiled plans to streamline the companys management structure in a bid to expedite decision-making processes. This marks the first step in a broader effort to transform the embattled German company, which has been under pressure from inv... Read More>>
Smurfit Kappa in Merger Talks with WestRock worth $19 Billion
Smurfit Kappa, a prominent player in the packaging industry, is reportedly engaged in merger discussions with its US counterpart, WestRock. This prospective merger has the potential to create a cardboard box-making powerhouse boasting a market value approaching $19 billion (€17.8 billion). Furt... Read More>>
RBC plans job cuts to take on anticipated economic softening
The Royal Bank of Canada is reportedly planning to reduce its workforce by approximately 1,800 jobs as part of cost-cutting measures, on account of the anticipated upcoming economic landscape. This decision comes after the country's largest bank surpassed analysts' predictions for the third ... Read More>>